# Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

> **NCT00044395** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 200 (—)

## Conditions studied

- Diabetic Neuropathies
- Diabetes Mellitus, Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** Ruboxistaurin mesylate

## Key facts

- **NCT ID:** NCT00044395
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 200 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044395, "Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00044395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*